Melphalan as a treatment for BRCA-related ovarian carcinoma: Can you teach an old drug new tricks?

Journal of Clinical Pathology

Volumn 64, Issue 10, 2011, Pages 924-926

  Osher, Deidra J ^a,b   Kushner, Yaël B ^a   Arseneau, Jocelyne ^a   Foulkes, William D ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; MELPHALAN;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HUMAN; LAPAROTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA2 PROTEIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053209565     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.086405     Document Type: Article

References (15)

1. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010;7:508-19.
2. Lambert HE, Gregory WM, Nelstrop AE, et al. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer 2004;14:772-8. (Pubitemid 39238159)
3. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-6.
4. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
5. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5.
6. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61.
7. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying a germline BRCA2 mutation. JOP 2008;9:305-8. (Pubitemid 351864891)
8. Huang F, Kushner YB, Langleben A, et al. Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. Nat Rev Clin Oncol 2009;6:488-92.
9. Hasan J, Jayson GC. Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer 2003;88:1828-30. (Pubitemid 36829654)
10. Evers B, Schut E, van der Burg E, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108.
11. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010;31:372-80.
12. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996;355:41-57. (Pubitemid 26275503)
13. Singh V, Parmar D, Singh MP. Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? Cancer Invest 2008;26:769-83.
14. Samaritani R, Corrado G, Vizza E, et al. Cyclophosphamide "metronomic"chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 2007;7:65.
15. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009;16:7-15.